Navigation Links
Dietary supplements discouraged for prostate cancer patients
Date:3/8/2010

Prostate-specific dietary supplements should not be taken during radiation therapy treatments because they have been shown to increase the radiosensitivity of normal prostate cell lines, leading to normal tissue complications, according to a study in the March issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

Many prostate cancer patients choose to take nutritional supplements to improve or increase sexual potency and alleviate symptoms associated with poor prostate health. Some studies show that about half of prostate cancer patients use an herbal or dietary supplement and most do so without discussing it with their doctor.

Researchers at William Beaumont Hospital in Royal Oak, Mich., sought to determine if three widely used commercial prostate-specific dietary supplements changed the radiosensitivity of normal prostate and/or androgen-positive and -negative prostate tumor cell lines. There have been published reports of negative clinical effects for some tumor sites from the use of certain dietary supplements after chemotherapy, but the effect of dietary supplements on radiation therapy treatments is not well-known.

The study authors found that the cell growth and radiosensitivity of the malignant tumor cells were not affected by any of the supplements, but two of the supplements inhibited the growth rate of the normal prostate cell lines while a third supplement also increased the cellular radiosensitivity of some normal cell lines by inhibiting DNA repair.

"Cancer patients turn to supplements to aid in their treatments for a variety of reasons, but this study proves that what some patients believe is helping them may actually be harming them," Brian Marples, Ph.D., senior author of the study and a radiobiologist at William Beaumont Hospital and clinical research professor at Oakland University William Beaumont School of Medicine,
'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Dietary factors influence ovarian cancer survival rates
2. Researchers develop dietary formula that maintains youthful function into old age
3. Even small dietary reductions in salt could mean fewer heart attacks, strokes and deaths
4. Dietary supplements manufacturers gain new tool to help ensure quality products
5. Two dietary oils, two sets of benefits for older women with diabetes
6. Following the dietary guidelines may slow heart disease in women
7. Desert woodrats switch one dietary poison for another
8. Desert woodrats switch one dietary poison for another
9. Results of the third school nutrition dietary assessment study published
10. Annual Bibliography of Significant Advances in Dietary Supplement Research 2007
11. The dietary supplement genistein can undermine breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... (WSU) Laboratory for Atmospheric Research is leading a nationwide ... the distribution of natural gas. Beginning this month, ... Lamb will quantify methane emissions throughout local gas systems ... data to estimate a national methane emissions rate for ...
... the University of Michigan have identified a new potential ... alternative or complementary therapy to statins. Scientists ... Sciences Institute inhibited the action of a gene responsible ... of the liver to remove cholesterol from the blood ...
... animals are frequently observed scavenging on other animals whether it ... or a buzzard swooping down on a dead animal. However, ... difficult, and often overlooked in marine food web studies. , ... titled, " White sharks ( Carcharodon carcharias ) scavenging on ...
Cached Biology News:Methane emissions from natural gas local distribution focus of new study 2Methane emissions from natural gas local distribution focus of new study 3U-M researchers find new way to clear cholesterol from the blood 2Great white sharks 2
(Date:7/28/2015)... LONDON , July 29, 2015 ... on acquiring, rapidly developing and commercialising ... human health   Highly experienced management team; ...     Mereo BioPharma Group Ltd ... successfully raised $119m ( c. £76.5m), gross, from blue ...
(Date:7/28/2015)... Virginia (PRWEB) , ... July 29, 2015 , ... The new Xsample 530 sample ... It handles a wide range of liquid viscosities – from less than 12,000 mPas (internal ... 12 mL vials. , What immediately catches the eye about Xsample 530 is its ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... helped by hearing aids achieved significant and sometimes profound ... hybrid cochlear implant devices, according to a new multicenter ... In the study, described online ahead of ... 10 medical centers and private clinics in ...
(Date:7/28/2015)... UK (PRWEB) , ... July 28, 2015 , ... ... reached more than EUR 1.022 billion in 2013; while production volume reached close ... the leading producing country with a share of 75.5% of the region’s total ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3
... of the Edmonton technology community and its companies and prove how ... ... Edmonton, AB (PRWEB) October 27, 2008 -- Edmontonians, a ... Visionaries--Insight, Innovation, Ingenuity project with the goal of increasing ...
... complement inhibitor to be tested in AMD patients, ... a,privately held biotechnology company developing medicines for the ... the Company,will be presenting its ASaP Phase I ... the Retina Subspecialty Day at the American,Academy of ...
... Osteoporosis Medications, PHILADELPHIA, Oct. 27 People ... for serious atrial fibrillation (AF), or,irregular heartbeats, according ... 2008, the 74th annual international scientific assembly of ... people taking,alendronate or zoledronic acid, two common medications ...
Cached Biology Technology:Edmonton's Technology Community: Using Social Media to Raise Awareness 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 3Osteoporosis Drugs Increase Risk for Heart Problems 2